Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07511543 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy

Study acronym: LEAST
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later across 2 updates Jun 30, 2028 → Oct 31, 2028
Primary endpoint removed 2 → 1 primary endpoints
Enrollment reduced 88% 826 → 100 participants
Primary endpoint added 1 → 2 primary endpoints
See other at-risk trials from Population Health Research Institute

Record History

  1. Eligibility criteria expanded, about 19 words Secondary endpoints: details revised at 2 of 2 entries · Study description revised Show 2 more changesShow less
    • Secondary endpoints: details revised at 2 of 2 entries
    • Study description revised
  2. Primary endpoint(s) modified Enrollment reduced: 826 → 100 participants · Phase changed: Phase 3 → Phase 2 · Primary completion moved earlier from Sep 30, 2031 to Oct 31, 2028 · 4 morev4 Show 7 more changesShow less
    • Enrollment reduced: 826 → 100 participants
    • Phase changed: Phase 3 → Phase 2
    • Primary completion moved earlier from Sep 30, 2031 to Oct 31, 2028
    • Start date: Sep 30, 2026 to Oct 31, 2026
    • Completion moved earlier from Dec 30, 2031 to Jan 31, 2029
    • Secondary endpoints: 7 to 2
    • Study description shortened, about 27 words

    See this version in full on ClinicalTrials.gov ↗

  3. Primary completion pushed from Jun 30, 2028 to Sep 30, 2031 Primary endpoint(s) modified · Phase changed: Phase 2 → Phase 3 · Enrollment increased: 100 → 826 participants · 4 morev3 Show 7 more changesShow less
    • Primary endpoint(s) modified
    • Phase changed: Phase 2 → Phase 3
    • Enrollment increased: 100 → 826 participants
    • Start date: Jun 30, 2026 to Sep 30, 2026
    • Completion pushed from Jun 30, 2028 to Dec 30, 2031
    • Secondary endpoints: 2 to 7
    • Study description expanded, about 27 words

    See this version in full on ClinicalTrials.gov ↗

  4. Re-verified, no change to tracked fieldsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Endovascular thrombectomy (EVT) is a procedure that improves recovery for people who suffer from a stroke by removing blood clots from large blood vessels in the brain. However, even with this treatment, over half of the patients either pass away or are left with serious disabilities within three months. This is partly because, even in cases of a successful EVT, brain tissue damage continues to grow. Extent of brain damage is a major factor in how well a patient recovers. Studies in animals have shown that a drug called semaglutide might help protect the brain and improve recovery after a stroke. Semaglutide is currently used for the treatment of diabetes and obesity and is given as a weekly injection under the skin. The investigators are hoping to test whether giving semaglutide to stroke patients undergoing EVT can improve their recovery. A very large study at many hospitals is needed to answer this question. The investigators are starting with a smaller study to gain information on whether it is possible to perform a larger definitive one, and if so, how best to plan for it. In this first step we will study 100 patients with stroke who are scheduled for EVT in approximately 10 stroke centers across Canada. These patients will be randomly divided (like flipping a coin) into two groups: one will receive weekly semaglutide injections for 12 weeks, while the other will not receive the drug. The investigators will track how many patients agree to participate, how many stay in the study, and how well they follow the treatment plan. The investigators will also monitor the patients' recovery, overall health, and any side effects from the treatment. These results will provide important information to plan our larger study with the goal of reducing death rates and long-term disability in stroke patients undergoing EVT.
Trial Details
NCT Number NCT07511543
Lead Sponsor Population Health Research Institute
Conditions Ischemic Stroke
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov